Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the
tumor and by blocking the enzymes necessary for tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have
progressive metastatic differentiated thyroid cancer.